I had gone to try to placate my wife by looking like I was protecting the house from a snake she saw and when I came in and saw your post I thought the stock price was cratering. Then I saw what you were responding and it is not much better.
Ultimately if we can’t get scripts moving it will be difficult to execute any other facets of the business. Curious to see how uptake in the EU compares to what we see here.
No Lovaza or Generic V being covered in the EU so hopefully a different story for us.
Is it possible that the Lovaza problem stems from the fact that docs have been prescribing it for a long time and both they and their patients are just reticent to switch? Haven’t looked close enough at L scripts over time to know if that is plausible.
Market Data 
Markets 
AI
